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We thank Dr. Sise and co-workers very much for their
letter and interest in our recent publication.1 We
appreciate them sharing their stratified analysis among
the subset of their patients with chronic kidney disease
from their provocative study.2
We would like to make a clarification regarding the
statement ‘it is not surprising that Hsu et al. found that
serum creatinine cannot distinguish between natural pro-
gression of CKD and acute-on-chronic disease.’ What we
had said was that ‘Among patients with very advanced
chronic kidney disease, it may be difficult to distinguish
between the final stages of progression to end-stage renal
disease from potentially reversible acute-on chronic renal
failure so the very high odds ratio observed among
those with estimated GFR of o15 ml per min per 1.73 m2
must be interpreted with caution.’1 Using direct medical
records review of a random sample of 100 patients with
baseline estimated GFR o45 ml/min per 1.73 m2, we
demonstrated that we were able to identify accurately cases
of acute-on-chronic kidney disease. As described in the
paper, a board-certified nephrologist confirmed that 100% of
the time, our algorithm captured true cases of acute renal
failure/acute kidney injury and did not mistakenly include
cases of progression of chronic kidney disease. The etiology
of these 100 cases of acute on chronic renal failure are
shown below and are comparable to that reported in prior
studies.3
We agree completely that neutrophil gelatinase-
associated lipocalin and other biomarkers are an exciting
area of research in acute kidney injury. Currently these
biomarkers are being validated against ‘gold standard’
definitions of acute kidney injury as determined by
changes in serum creatinine.2,4,5 Our understanding of
the epidemiology of acute kidney injury and the role of
biomarkers should be greatly enhanced with the antici-
pated launch of the NIH-NIDDK sponsored study of the
natural history of acute kidney injury (http://grants.
nih.gov/grants/guide/rfa-files/RFA-DK-07-009.html).
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Does postmenopausal hormone
therapy influence renal function?
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To the Editor: Ahmed et al1 investigate a facet of
postmenopausal hormone therapy (HT) hereunto unad-
dressed by the Women’s Health Initiative, but their
epidemiologic approach raises several questions.
The authors chose age 66 as the minimal age for
enrollment (mean age 470), and subjects were largely
plagued by various chronic ailments and renal compromise
(estimated glomerular filtration rate o90 ml/min per
1.73 m2). As younger (o age 60) women with normal renal
function account for the overwhelming majority of HT
utilization, why did the investigators select a markedly
Etiology
Decreased renal perfusion (including volume contraction,
congestive heart failure, hypotension, cardiac arrest)
76
Medication related 0
Radiocontrast media 6
Postoperative 6
Sepsis 21
Others 6
Total exceeds 100 as some cases had more than one contributing etiology
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